Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.

Pei ZhangJianchun DuanHua BaiZhijie WangShugeng GaoFengwei TanYushun GaoXin WangRui WanJiachen XuXiran HeXiaoshuang FengRuofei Yu Jing SunZhe ZhaoKailun FeiNi LiJie HeJie Wang

Published in: Thoracic cancer (2020)

ACT was not significantly associated with improved five-year OS in stage IB-IIA NSCLC patients. However, it was correlated with better DFS before or after PSM. Patients with VPI in the 3 < tumor ≤ 4 cm subgroup may benefit from ACT.

Keyphrases

end stage renal disease
ejection fraction
small cell lung cancer
newly diagnosed
chronic kidney disease
prognostic factors
clinical trial
advanced non small cell lung cancer
patient reported outcomes
tyrosine kinase
patient reported
study protocol
brain metastases